View Older Stories View More Recent Stories
-
Investor overreaction is a buying opportunity in this MedTech stock: Morgan Stanley
-
Doximity Inc (DOCS) PT Lowered to $25 at BMO Capital Amid Near-Term Headwinds
-
Doximity Inc (DOCS) PT Lowered to $37 at Truist Securities
-
Doximity Inc (DOCS) PT Lowered to $55 at Needham
-
Doximity Inc (DOCS) PT Lowered to $40 at Piper Sandler
-
JPMorgan Upgrades Doximity Inc (DOCS) to Neutral
-
After-hours movers: Amazon, Roblox, Bloom Energy, Reddit, Molina Health and more
-
Doximity, Inc. (DOCS) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
-
Doximity Inc (DOCS) PT Lowered to $70 at BofA Securities
-
Goldman Sachs Upgrades Doximity Inc (DOCS) to Buy
-
Raymond James on Doximity Inc (DOCS): 'We likely aren’t done with the competitive dynamic narrative'
-
RBC Capital Starts Doximity Inc (DOCS) at Outperform
-
Raymond James comments on Doximity, Inc. (DOCS) post webinar: 'The expert hasn’t seen any changes to budgets for DTC spending'
-
Truist Securities Upgrades Doximity Inc (DOCS) to Buy
-
Evercore ISI on Doximity Inc (DOCS): 'we expect Doximity to remain the anchor professional and commercial platform'
-
This software stock has a 'Strong Buy' rating at Raymond James
-
Doximity settles securities lawsuit for $31 million
-
Raymond James on Doximity Inc (DOCS): 'We would continue to buy shares on the recent pullback'
-
Piper are buyers of 'these high quality, profitable, growth' stocks
-
Piper Sandler: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch'
-
BofA Securities on Doximity Inc (DOCS): 'No shift from DTC, but HCP growth is accelerating'
-
Piper: 'We Would be Buyers of DOCS and PHR Following Pharma Marketing KOL Lunch in Boston'
-
Morgan Stanley Upgrades Doximity Inc (DOCS) to Overweight
-
These are the best U.S. healthcare tech and distribution stocks to buy: Barclays
-
Wells Fargo Reiterates Equal Weight Rating on Doximity Inc (DOCS)
-
Raymond James Upgrades Doximity Inc (DOCS) to Strong Buy
-
Doximity, Inc. (DOCS) Tops Q2 EPS by 7c, Offers Guidance
-
BofA Securities Upgrades Doximity Inc (DOCS) to Buy
-
JPMorgan Downgrades Doximity Inc (DOCS) to Underweight
-
BofA Securities Reiterates Neutral Rating on Doximity Inc (DOCS)
-
Raymond James Reiterates Outperform Rating on Doximity Inc (DOCS)
-
BofA on Neutral Rated Doximity Inc (DOCS): 'We come away slightly more positive on DOCS'
-
Goldman Sachs Downgrades Doximity Inc (DOCS) to Sell
-
Doximity Inc (DOCS) PT Raised to $67 at Canaccord Genuity
-
Raymond James on Doximity Inc (DOCS): 'We still believe that Doximity’s reach of 80%+ of physicians on the platform represents a formidable moat'
-
Doximity Inc (DOCS) PT Raised to $75 at BofA Securities
-
Doximity, Inc. (DOCS) Announces Resignation of Chief Compliance Officer
-
Doximity Inc (DOCS) PT Raised to $69 at Piper Sandler
-
Doximity Inc (DOCS) PT Raised to $62 at Morgan Stanley
-
Doximity Inc (DOCS) PT Raised to $79 at Leerink Partners
-
Doximity Inc (DOCS) PT Raised to $75 at Raymond James
-
Doximity Inc (DOCS) PT Raised to $75 at Evercore ISI
-
Doximity, Inc. (DOCS) Tops Q1 EPS by 6c; offers guidance
-
Leerink Partners Reiterates Outperform Rating on Doximity Inc (DOCS)
-
Doximity Inc (DOCS) PT Raised to $62 at Wells Fargo
-
Wells Fargo Reiterates Equal Weight Rating on Doximity Inc (DOCS)
-
Evercore ISI Upgrades Doximity Inc (DOCS) to Outperform
-
Doximity Inc (DOCS) PT Raised to $62 at BofA Securities
-
Doximity, Inc. (DOCS) Jumps Following Bloomberg Report Trump Administration Said To Consider Crackdown On Pharma Ads
-
Doximity, Inc. (DOCS) Announces Resignation of Chief Strategy Officer

